feedback

Course Director

John R. Wingard, MD
John R. Wingard, MD

University of Florida Health Cancer Center
Bone Marrow Transplant Program
University of Florida College of Medicine
Gainesville, Florida

Faculty

Kieren Marr
Kieren Marr, MD

Johns Hopkins University
Baltimore, Maryland

Accredited by

The Medical College of Wisconsin

Activity Details

Credit Types:CME
Credit Amount:1.0 Credits
Release Date:2016-May-13
Expiration Date:2017-May-12
Estimated Time for Completion:60 mintues
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

The practice of hematopoietic stem cell transplantation (HCT) has undergone many changes that affect the likelihood that a given patient will develop an invasive fungal infection (IFI). The risks for IFI and the types of IFI that may occur are not constant over the time course after transplantation. IFIs vary with the events that occur during the pre-engraftment neutropenic period, as well as the early and late post-engraftment periods. A number of well-recognized transplant recipient-related, procedure-related, and complication-related factors play a role in the likelihood of IFI. The interaction of these factors over a given patient’s journey through HCT conspires to promote or reduce the overall IFI risk and set the conditions for the development of any given IFI. Despite the availability of a large array of antifungal agents (ie, polyenes, azoles, and echinocandins), these infections continue to represent a significant risk to HCT recipients. Clearly, there are multiple barriers that stand between HCT recipients and implementation of effective therapy for the prevention and treatment of IFIs.

This activity examines evidence-based strategies to minimize the burden of IFIs in HCT recipients. Expert insight on real-world patient scenarios will elucidate the changing, modern approach to IFI prevention and management.

Upon completion of this activity, participants should be better able to:

  • Discuss the changing epidemiology of invasive fungal infections (IFIs) in hematopoietic stem cell transplant (HCT) recipients
  • Identify risk factors for IFIs in HCT recipients
  • Discuss the pharmacology, efficacy, and safety of current antifungal agents
  • Apply evidence-based, individualized strategies for the prevention and treatment (ie, empirical, pre-emptive, and targeted therapy) of IFIs in HCT recipients, recognizing the role of new antifungal agents

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, transplant specialists, advanced practice hematology/oncology nurses, bone marrow transplant clinical nurse specialists, and pharmacists involved in the care of patients undergoing hematopoietic stem cell transplantation.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: May 13, 2016 - May 12, 2017
Time to Complete: 60 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

John R. Wingard, MD
Price Eminent Scholar and Professor of Medicine
Associate Director for Clinical Research, University of Florida Health Cancer Center
Director, Bone Marrow Transplant Program
Division of Hematology/Oncology
University of Florida College of Medicine
Gainesville, Florida

John R. Wingard, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Ansun BioPharma; Astellas Pharma US, Inc.; Gilead; and Merck & Co., Inc.
Speakers Bureau participant with Pfizer Inc.

Faculty

Kieren Marr, MD
Professor of Medicine and Oncology
Director, Transplant and Oncology Infectious Diseases
Associate Vice Chair for Innovation and Commercialization, Dept. of Medicine
Johns Hopkins University
Baltimore, Maryland

Kieren Marr, MD, has a financial interest/relationship or affiliation in the form of:
Other Financial or Material Support: Dr. Marr is a founder of Life Sciences Consulting, LLC, which is a paid consultant to: Astellas Pharma US, Inc.; Chimerix; Cidara Therapeutics; F2G; Genentech Inc.; Merck & Co., Inc.; Pfizer Inc.; RevMed; and Theravance Biopharma.
Under a licensing agreement between MycoMed Technologies, LLC and the Johns Hopkins University, Dr. Marr is entitled to royalties on an invention for fungal diagnostics.
Dr. Marr also is a founder of MycoMed and serves as its Chief Scientific Officer. All arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by educational grants from Astellas and Merck & Co., Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView Press or any of its partners, providers, and/or supporters.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.